rs6983267
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
rs6983267
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.
|
30529582 |
2019 |
rs6983267
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
We confirmed that the homozygous T/T allele of rs6983267 c-MYC indicated an interaction between dietary seaweed intake and both overall CRC and rectal cancer (CRC OR [95% CI] = 0.52 [0.34-0.81], P for interaction = 0.015; rectal cancer = 0.45 [0.25-0.79], P for interaction = 0.007, T/T carriers with high total seaweed intake vs. T/T carriers with low total seaweed intake).
|
31300834 |
2019 |
rs6983267
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
<i>CCAT2</i> rs6983267 was associated with the risk of CRC per</span> se (<i>p</i> < 0.01).
|
30841568 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRAF inhibitor AZ304.
|
29755114 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In this study, we explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms.
|
29534162 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Further preclinical and clinical investigations are needed to clarify the role of non-V600E mutations in CRC.
|
30463788 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs.
|
30009773 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Here, we investigate molecular responses upon single and multi-target treatments, over time, using BRAF(V600E) mutant colorectal cancer cells as a model system.
|
29970458 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Colorectal cancer (CRC) is one of the most common cancers worldwide, with 8-10% of these tumours presenting a BRAF (V600E) mutation.
|
30087414 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
BRAF inhibitor vemurafenib, and subsequent MAPK pathway inhibitors trametinib and SCH772984, significantly increased SPINK1 secretion in V600E CRC cell lines Colo205 and HT-29 with a concomitant decrease in trypsin-1 and -2 secretion.
|
29193645 |
2018 |
rs12953717
|
|
|
0.900 |
GeneticVariation |
BEFREE |
For SNPs on 18q21 (rs12953717 and rs4464148) and 20q13 (rs4925386), alleles that correlate with higher risk for the development of CRC are associated with shorter disease free survival (DFS).
|
29119627 |
2018 |
rs12953717
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The dominant model of SMAD7 rs12953717 (CT + TT genotypes) significantly increased CRC risk (HR=2.17, 95% CI=1.12-4.16) when compared to the wild-type CC genotype.
|
30275229 |
2018 |
rs4939827
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Micro RNA-375 and rs4939827 SNP in SMAD7 could be considered as potential markers for detecting and early diagnosing CRC patients.
|
28374902 |
2018 |
rs6983267
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.
|
28960316 |
2018 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In particular, both homozygous TT and heterozygous CT genotypes of rs10505477, as well as the GG and TG genotypes of rs6983267, were associated with risk of colorectal cancer.Our study provides summary evidence that common variants in the 8q24 are associated with risk of colorectal cancer in this large-scale research synopsis and meta-analysis.
|
30170403 |
2018 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Our study highlighted the high CRC risk of people carrying rs6983267 G and rs11777210 C alleles, and provided possible biological mechanism of the interaction.
|
29267898 |
2018 |
rs6983267
|
|
T |
0.900 |
GeneticVariation |
GWASCAT |
Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
|
30104761 |
2018 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Meta-analysis showed association between SNPs rs6983267, rs11694911 and rs2302615 with CRC risk reduction (All P<0.05).
|
29425227 |
2018 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
GWASCAT |
GWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12.
|
29471430 |
2018 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In conclusion, we show that several CRC risk SNPs detect subpopulations of rectal cancer patients with poor prognosis, and that rs6983267 probably affects prognosis through interfering with the resistance of cancer cells to CRT.
|
29119627 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Mutation analysis of 66 arbitrary selected colorectal carcinomas revealed that CD274-positive tumors usually (88%) carried the BRAF V600E mutation.
|
27813511 |
2017 |